<?xml version='1.0' encoding='utf-8'?>
<document id="29060457"><sentence text="A pharmacokinetic model of drug-drug interaction between clopidogrel and omeprazole at CYP2C19 in humans."><entity charOffset="57-68" id="DDI-PubMed.29060457.s1.e0" text="clopidogrel" /><entity charOffset="73-83" id="DDI-PubMed.29060457.s1.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.29060457.s1.e0" e2="DDI-PubMed.29060457.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29060457.s1.e0" e2="DDI-PubMed.29060457.s1.e1" /></sentence><sentence text="Clopidogrel is a thienopryridine antiplatelet agent commonly used in the management of cardiovascular diseases"><entity charOffset="0-11" id="DDI-PubMed.29060457.s2.e0" text="Clopidogrel" /><entity charOffset="17-32" id="DDI-PubMed.29060457.s2.e1" text="thienopryridine" /><pair ddi="false" e1="DDI-PubMed.29060457.s2.e0" e2="DDI-PubMed.29060457.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29060457.s2.e0" e2="DDI-PubMed.29060457.s2.e1" /></sentence><sentence text=" Clopidogrel is metabolized by hepatic CYP2C19 and CYP2B6, therefore, co-administration of clopidogrel and CYP2C19 inhibitors can alter pharmacokinetics of clopidogrel"><entity charOffset="1-12" id="DDI-PubMed.29060457.s3.e0" text="Clopidogrel" /><entity charOffset="91-102" id="DDI-PubMed.29060457.s3.e1" text="clopidogrel" /><entity charOffset="156-167" id="DDI-PubMed.29060457.s3.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.29060457.s3.e0" e2="DDI-PubMed.29060457.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29060457.s3.e0" e2="DDI-PubMed.29060457.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29060457.s3.e0" e2="DDI-PubMed.29060457.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29060457.s3.e1" e2="DDI-PubMed.29060457.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29060457.s3.e1" e2="DDI-PubMed.29060457.s3.e2" /></sentence><sentence text=" Omeprazole is a proton pump inhibitor used for decreasing gastric acid production"><entity charOffset="1-11" id="DDI-PubMed.29060457.s4.e0" text="Omeprazole" /></sentence><sentence text=" Omeprazole is known to be a potent inhibitor of CYP2C19"><entity charOffset="1-11" id="DDI-PubMed.29060457.s5.e0" text="Omeprazole" /></sentence><sentence text=" Thus when the drugs are simultaneously administered, clopidogrel plasma concentration levels can be increased"><entity charOffset="54-65" id="DDI-PubMed.29060457.s6.e0" text="clopidogrel" /></sentence><sentence text=" However, plasma levels of the active metabolite of clopidogrel can be significantly decreased, thereby, its antiplatelet activity is reduced"><entity charOffset="52-63" id="DDI-PubMed.29060457.s7.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="We aimed to develop a mathematical model describing a drug-drug interaction between clopidogrel and omeprazole in humans"><entity charOffset="84-95" id="DDI-PubMed.29060457.s9.e0" text="clopidogrel" /><entity charOffset="100-110" id="DDI-PubMed.29060457.s9.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.29060457.s9.e0" e2="DDI-PubMed.29060457.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29060457.s9.e0" e2="DDI-PubMed.29060457.s9.e1" /></sentence><sentence text="" /><sentence text="Searching for pharmacokinetic interaction studies between clopidogrel and omeprazole in humans was performed in PubMed"><entity charOffset="58-69" id="DDI-PubMed.29060457.s11.e0" text="clopidogrel" /><entity charOffset="74-84" id="DDI-PubMed.29060457.s11.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.29060457.s11.e0" e2="DDI-PubMed.29060457.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29060457.s11.e0" e2="DDI-PubMed.29060457.s11.e1" /></sentence><sentence text=" Six studies were selected into our modeling purposes to develop 3 mathematical models (i" /><sentence text="e" /><sentence text=" 4 studies for clopidogrel alone, 1 study for omeprazole alone and 1 study for clopidogrel-omeprazole interaction)"><entity charOffset="15-26" id="DDI-PubMed.29060457.s14.e0" text="clopidogrel" /><entity charOffset="46-56" id="DDI-PubMed.29060457.s14.e1" text="omeprazole" /><entity charOffset="79-90" id="DDI-PubMed.29060457.s14.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.29060457.s14.e0" e2="DDI-PubMed.29060457.s14.e0" /><pair ddi="false" e1="DDI-PubMed.29060457.s14.e0" e2="DDI-PubMed.29060457.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29060457.s14.e0" e2="DDI-PubMed.29060457.s14.e2" /><pair ddi="false" e1="DDI-PubMed.29060457.s14.e1" e2="DDI-PubMed.29060457.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29060457.s14.e1" e2="DDI-PubMed.29060457.s14.e2" /></sentence><sentence text=" Subsequently, concentration-time course data from the selected studies were extracted" /><sentence text=" Computer codes and simulations were performed using the Advanced Continuous Simulating Language Extreme (ACSLX) program" /><sentence text="" /><sentence text="We successfully developed 3 mathematical models which are able to describe all of the datasets" /><sentence text="" /><sentence text="Our clopidogrel-omeprazole pharmacokinetic interaction model with a description of competitive inhibition at CYP2C19 could successfully describe concentration-time courses from the selected datasets" /><sentence text=" Our interaction model may be useful in predicting plasma levels of clopidogrel and its active metabolite"><entity charOffset="68-79" id="DDI-PubMed.29060457.s21.e0" text="clopidogrel" /></sentence><sentence text="" /></document>